RUBIN’S REFLECTIONS

Follow on Twitter @IBDMD

Message to Dr. Rubin’s Patients Related to COVID-19 Boosters

Aug 13, 2021

Dear Friends and Patients, I hope this message finds you well. Please excuse the group nature of this message, but I did want to reach out with the latest update about COVID-19, and vaccinations. If you want to skip right to the booster info, scroll down to #5 below....

Tweetorial to Provide Updates on COVID-19 for Patients with IBD

Jul 30, 2021

View Twitter Thread To watch me deliver the full lecture and view the presentation, click here. I recently gave a lecture about COVID-19 and vaccination with specific information for patients with IBD. This lecture was recorded on July 21st, before the CDC issued...

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study

Apr 18, 2021

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study David T. Rubin View Twitter Thread I've previously commented about the CLARITY IBD Study (Kennedy, et al). paper in this forum, but it bears repeating and further...

SARS Vaccine and IBD Tweetorial Summary from December 1

Dec 5, 2020

SARS Vaccine and IBD Tweetorial Summary from December 1 David T. Rubin View Twitter Thread Here are my thoughts and a few updates about SARS-CoV-2 vaccines, and also about important implications for our IBD patients. Development of multiple SARS-CoV-2 vaccines in the...

Approach to Management and Interpretation of Testing Results in Patients with IBD, with Particular Attention to Restarting Therapy

Apr 21, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine As testing for SARS-CoV-2 is expanded and serologic antibody testing becomes available, we are faced with a number of different clinical scenarios. I have outlined the different situations...

Three waves of Illness from the COVID-19 Pandemic

Apr 1, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine I've been thinking about what comes next, and how can we get ahead of this, and propose the following for consideration. I believe that there will be three waves of illness from the...

Long-Duration Vancomycin Linked to Lower Rates of C. diff Recurrence in IBD

by dtrubin | December 6, 2019 | In the Press | 0 Comments

Pritzker medical student Donald Lei's manuscript was accepted to the American Journal of Gastroenterology. Reuters Health Information reported on the study with comments by Dr. Rubin. "Our study did in fact demonstrate significantly reduced rates of recurrence...

Definition of “healing” and sustained remission

by dtrubin | December 6, 2019 | histology, normalization, Rubin's Reflections | 0 Comments

The FDA and others have been interested in the role of histology for assessing “deeper” levels of disease control, with the premise that biopsy may reflect the state of the disease more accurately and perhaps more objectively than endoscopy, and certainly more than...

IBD Drive Time Podcast: Ethical Issues in Clinical Trials

by David Rubin | October 19, 2023 | In the Press | 0 Comments

Take a listen to the third episode of a four-part series wherein Professor Rubin guest-hosts the Gastroenterology Learning Network's IBD Drive Time and discusses the ethics of clinical trials in IBD, as well as challenges to recruitment, alongside Professor Severine...

IBD As We Age: Thoughts on Treatment and Management For Age 40 and Beyond

by dtrubin | December 4, 2019 | QoL, Rubin's Reflections | 0 Comments

There is a growing number of people diagnosed with IBD who are defined as “elderly”. This varies in definition but can be considered those who have IBD older than 50 or older than 60 or 65. I prefer the World Health Organization definition of >65. The two different...

UChicago Medicine Patient First in the World to Receive Ulcerative Colitis Drug Since FDA Approval

by David Rubin | September 23, 2024 | In the Press | 0 Comments

A University of Chicago Medicine patient became the first person with ulcerative colitis in the world to receive the drug guselkumab (Tremfya) since its Sept. 11 approval by the FDA for treating moderate to severe ulcerative colitis. Tremfya has been used for many...

How UC Affects Your Sex Life

by David Rubin | December 16, 2020 | In the Press | 0 Comments

Many people with Ulcerative Colitis wonder whether it’s possible to have a satisfying sex life. Dr. David Rubin discusses how to address the situation with your physician and partner. Read more here.

How Does SARS-CoV-2 Become COVID-19 and How Can We Stop It?

by dtrubin | March 26, 2020 | Coronavirus, Rubin's Reflections | 0 Comments

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine Dear Colleagues, Here is my understanding of the different stages through which SARS-CoV-2 becomes COVID-19. I also added some thoughts on how we can prevent these stages and treat patients....

Pregnancy in the Setting of the SARS-CoV-2 Pandemic

by dtrubin | March 26, 2020 | Coronavirus, Rubin's Reflections | 0 Comments

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine Dear Colleagues, A lot of concern has recently come up regarding pregnancy in the setting of the SARS-CoV-2 pandemic. Here are some key points I found on this issue: Pregnancy is a state of...

VIDEO: Social media has been a ‘life saver’ during COVID-19 pandemic

by David Rubin | April 19, 2021 | In the Press | 0 Comments

Watch this video exclusive, to hear David T. Rubin, MD highlight how the COVID-19 pandemic changed the use of social media.

How IBD Can Affect Patients’ Career and School Choices

by dtrubin | December 3, 2019 | QoL, Rubin's Reflections | 0 Comments

IBD, perhaps more than other chronic illnesses, can have a definite impact on a patient’s career choices and school performance. Therefore, I have definitely seen patients make decisions that are affected by their IBD. However, more often, I’ve seen patients overcome...